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Running Title: New SFTPC mutations associated with lung disease. 
ABSTRACT 
Mutations in the surfactant protein C gene (SFTPC) have been recently associated with the 
development of diffuse lung disease, particularly sporadic and familial interstitial lung disease 
(ILD). We have investigated the prevalence and the spectrum of SFTPC mutations in a large 
cohort of infants and children with diffuse lung disease and suspected with surfactant 
dysfunction. One hundred twenty-one children were first screened for the common SFTPC 
mutation, p.Ile73Thr (I73T). Ten unrelated patients were shown to carry this mutation. The 
I73T mutation was inherited in 6 cases, and appeared de novo in 4. The 111 patients without the 
I73T mutation were screened for the entire coding sequence of SFTPC. Of these, eight (seven 
unrelated) subjects were shown to carry a novel mutant allele of SFTPC. All these seven new 
mutations are located in the BRICHOS domain except the p.Val39Ala (V39A) mutation, which 
is in the surfactant protein C (SP-C) mature peptide. Our results confirm that SFTPC mutations 
are a frequent cause of diffuse lung disease, and that I73T is the most frequent SFTPC mutation 
associated with diffuse lung disease.  
 









Diffuse lung disease in children, including interstitial lung disease (ILD) and chronic 
lung disease, is a rare heterogeneous group of chronic disorders characterized by impaired gas 
exchange 1. Recent studies suggest that surfactant deficiency plays a role in the pathogenesis 2. 
Pulmonary surfactant is a complex mixture of proteins and lipids that prevents collapse at end 
expiration by reducing surface tension at the air-water interface of the lung alveoli. 
Surfactant protein C (SP-C), a hydrophobic protein critically involved in surfactant 
homeostasis 3, is expressed by alveolar type II epithelial cells and encoded by a single gene 
located on chromosome 8 (8p21.3) called SFTPC. Human SFTPC gene is organized into 6 
exons (I through V coding, VI untranslated). SP-C is synthesized as a 197-amino acid 
proprotein (proSP-C) that undergoes multiple processing steps to the mature SP-C peptide of 35 
amino acids, to be finally released in the alveoli associated with the other surfactant proteins 
and phospholipids 3. Nogee et al. first described a SFTPC mutation in 2001 4. The mutation, 
c.435+1G>A, located at the first base of intron 4 alters the normal donor splice site and results 
in the skipping of exon 4 and the deletion of 37 amino acids in the carboxy-terminal domain of 
proSP-C. This mutation was observed in one allele of a patient suffering from chronic 
interstitial pneumonitis and was inherited following a dominant pattern. To date, 13 SFTPC 
mutations have been identified 4-11. They always occur in one single allele and have been 
associated with diffuse lung disease in children and adults. The mutation I73T (c.218 T>C) is 
the more prevalent mutation; others have been described in only one family. Dominant 
transmission with variable penetrance has been confirmed in familial cases, but a number of 
sporadic cases have also been reported with a de novo mutation. The phenotype associated with 
SFTPC mutations appears to be very variable. Indeed, neonatal forms leading to death in the 
first years of life as well as childhood and adult forms with chronic respiratory disease have 
been reported. Single nucleotide polymorphisms (SNPs) have also been detected both in the 
coding and non-coding sequence, with unclear consequences on proSP-C processing and 
function 2. 
 The variable phenotype with unspecific biological findings makes the genetic diagnosis 
of SP-C inherited disease essential. Thus, the present study aims to investigate SFTPC 
variations in a large population of 121 children (120 unrelated) with diffuse lung disease and 
suspected surfactant dysfunction.  
 
MATERIALS AND METHODS 
Patients 
One hundred and twenty-one newborns/children (60 male, 61 female) diagnosed with 
diffuse lung disease were recruited over a 5-year period (2002–2007) through a national 
program on rare lung disease by several university hospital-based pediatric pulmonology 
practices (Hôpital Armand Trousseau, Paris; Hôpital Necker Enfants Malades, Paris; 
Groupement Hospitalier Est, Lyon and Centre Hospitalier Universitaire CHU Arnaud de 
Villeneuve, Montpellier). Seventy four patients originated from Europe, 24 from North Africa, 
13 from Africa, 9 from Reunion Island and 1 from French Antilles. Among the 121 patients 
with diffuse lung disease, 86 had respiratory distress, 59 presenting with neonatal onset and 18 
patients died. Clinical observations included family background, physical signs at presentation, 
chest radiography and computed tomography (CT), and histological lung analysis when 
available. The protocol was accepted by the Committee for the protection of individuals in 
Biochemical research as required by French legislation and written informed consent was 
obtained from the patients or their next of kin included in this study. 
The 121 patients where the common 121ins2 SFTPB mutation was initially ruled out 
were analyzed for the common I73T mutation. Then, the entire SFTPC coding sequence was 
performed in patients without the I73T mutation. 
 
Mutation Analysis 
Genomic DNAs were extracted from patients’ blood using an automated BioRobot EZ1 
workstation (Qiagen, Hilden, Germany). The common mutation I73T was screened using an 
allele specific amplification as previously published 12 and confirmed by the direct sequencing 
of exon 3.  The 5 coding exons of SFTPC and the exon-intron boundaries were analyzed by 
direct DNA sequencing of PCR products using the following primers: exon 1 sense 5’-
ACCCAGGTTTGCTCTTGCT-3’, exon 1 antisense 5’-TGAATGGATCTGGATAAGGAAA-
3’, exon 2 sense 5’-TGTTAGAATCCAGGCCACCT-3’, exon 2 antisense 5’-
CGTGCCTCTTTCCTTCTAGC-3’, exon 3 sense 5’- CTCTTGGGAAAGAGGGAAGC-3’, 
exon 3 antisense 5-‘GGGAGAGATGGATGTGGATG-3’, exon 4 sense 5’-
CTAGTATGACTCCCGTGCCC-3’, exon 4 antisense 5’-TGAGGAACAGTGCTTTACAGG-
3’, exon 5 sense 5’-TCAGCTGAGTCCACTCACTACC-3’, exon 5 antisense 5’-
GTACCGGTCTGTGAGCTTCC-3’. Sequencing reactions were performed with Big Dye 
Terminator cycle sequencing kits from Applied Biosytems (Foster city, CA) and run on an ABI 
Prism 3130 Genetic Analyzer. Sequences were analyzed using SeqScape software and 
compared with the reference sequence NM_003018.3. Mutations are named following the 
international nomenclature, starting at nucleotide 1 of the first codon (Human Genome 
Variation Society: Nomenclature for the description of sequences variation, 
http://www.hgvs.org/mutnomen/).  
Multiple protein alignments were performed using the software SIFT 
(http://blocks.fhcrc.org/sift/SIFT.html) and the search for polymorphisms was carried out using 
the dbSNP database (http://www.ncbi.nlm.nih.gov/SNP/). The effect of substitution on the 
splicing site was studied using the software NetGene2 
(http://www.cbs.dtu.dk/services/NetGene2/) and GeneSplicer Web Interface 
(http://www.tigr.org/tdb/GeneSplicer/gene_spl.html). 
The control population consisted of 50 individuals of European descent, 50 individuals of North 
African descent, 50 individuals from African descent and 50 individuals of Reunion Island 
descent, all of whom have no report of pulmonary disease.  
 
RESULTS 
We screened a cohort of 121 patients with diffuse lung disease for the mutation 
c.218T>C (p.Ile73Thr, I73T). SFTPC mutation is present in 18 (17 unrelated) patients and 
seven novel mutations are described.  
The I73T mutation was found in 10 patients without neonatal onset, eight presenting 
with respiratory viral infection. I73T was inherited in 6 cases. In 4 cases, I73T was sporadic and 
thus absent in both parents. The 111 patients without I73T mutation were screened for all the 
coding sequence and the exon-intron boundaries of SFTPC. Seven novel SFTPC variations 
were identified (Table 1). 
 
 
 Table 1.  Newly discovered SFPTC mutations. 
 
aNumbering relative to coding DNA reference sequence NM_003018.3 and starts at translation initiation site 
(ATG). 
bNumbering relative to NP_003009.2. 
M/F: Male/Female 
ILD: Interstitial Lung Disease 
*Twins 
#Death at 3 months 
 
Two mutations, C189Y and L194P, were inherited (Figure 1), whereas the mutations 
c.325-1G>A and c.424delC were sporadic and absent in the patient’s parents and probably 
appeared de novo. Samples of familial individuals of index cases with V39A, Q145H and 
L188P were unavailable. The novel variants segregated with the disease in the familial cases 
(C189Y and L194P) and have not been previously reported as polymorphisms, suggesting that 
they are pathogenic. In addition, each new variant was not detected in 100 control alleles of the 
same origin. The mutation c.325-1G>A located at the last base of intron 3 is presumed to 
abolish the normal acceptor splice site using the GeneSplicer prediction software, and to result 































































































proSP-C. The mutation c.424delC in exon 4 is a frameshift mutation that induces a premature 
stop codon at position 185. The variation c.435G>C resulting in the substitution of glutamine 
145 by histidine, involved the last base of exon 4. This substitution is supposed to abolish the 
donor splicing site of exon 4 following the software of splice site prediction, and to result in the 
skipping of exon 4. The V39A mutation is located in mature SP-C. The six other novel 
variations have been detected in the BRICHOS domain (Figure. 2). 
Interestingly, the age of onset was significantly lower in patients with new mutations 
compared with those carrying the I73T mutation (Table 2). No other significant differences 
between the two groups of patients were observed.  
 
Table 2.  Characteristics of patients with I73T and new SFTPC mutations. 
 




Patients n 18 10 8 




Age at onset (mean±sd in months)  
Viral infection at onset  







































                *p<0.01, Mann-Whitney 
 
DISCUSSION 
The identification of SP-C alterations has led to significant advances in the diagnosis of 
diffuse lung disease. Our study on a large cohort of patients confirms that the common mutation 
I73T in the SFTPC gene is a frequent cause of diffuse lung disease. In addition, we described 
seven new pathogenic SFTPC variants associated with respiratory diseases occurring during the 
first months of life.  
The mutation I73T has been first reported in one allele of an infant with severe 
respiratory insufficiency and a histological pattern of nonspecific interstitial pneumonia (NSIP) 
and pulmonary alveolar proteinosis (PAP) 7, 9. Furthermore, in a cohort of 116 children with 
ILD, this mutation was present in 7 cases and appeared to be common 12. The mutation was 
inherited or observed de novo. The phenotype associated with I73T was described as eminently 
variable, ranging from fatal cases to asymptomatic adult carriers 12, 13. In our cohort of 121 
patients with diffuse lung disease, we found 10 unrelated patients with diffuse lung disease 
harboring the I73T mutation. This result confirms the high frequency of this mutation in diffuse 
lung disease.  
Besides this frequent mutation, only 12 SFTPC mutations have been previously 
described. We report in this study seven new mutations. The splice site mutation c.325-1G>A is 
thought to affect the acceptor splice site of exon 4, and may result in the skipping of exon 4. 
Thus, this mutation probably has the same effect than the previously reported mutation 
c.435+1G>A affecting the donor site of exon 4 4. The deletion c.424delC induces the translation 
of an abnormal protein. The missense mutations V39A, Q145H, L188P, C189Y, and L194P are 
believed to be pathogenic because they have not been observed in control chromosomes of the 
same origin. Moreover, the amino acids involved are conserved in mammalian SP-C sequences, 
and the mutation segregates with the pulmonary disease in familial cases (C189Y and L194P). 
The phenotype associated with C189Y appeared to be variable, severe in the first months of life 
and asymptomatic in adults. In contrast, L194P is associated with pulmonary fibrosis in adults. 
The mutation V39A is the first valine of the polyvaline stretch of mature SP-C. The polyvaline 
stretch is believed to be a crucial actor of the secondary structure of SP-C. Indeed, studies of 
purified mature SP-C have shown that the polyvaline stretch is highly α-helical and capable of 
spanning phospholipids bilayers in the liquid crystalline phase 14.  
To date, most of the mutations previously identified in the SP-C gene are localized in 
the propeptide. In our study, with the exception of the V39A located in the mature peptide, the 
other new mutations are in the propeptide. Based on functional studies that ascertain the role of 
SFTPC mutations in the pathogenesis of diffuse lung disease, two mechanisms have been 
suggested 2, 10. First, owing to a heterozygous mutation, abnormal proSP-C could disrupt the 
regular processing of proSP-C within the cell and consequently inhibit SP-C production in the 
alveoli. This is the case for the I73T and E66K mutations altering intracellular trafficking 7, 10. 
Also, as shown in the Δexon4 and L188Q mutations, aberrant proSP-C forms aggregates that 
could be toxic for alveolar type II cells and induce an unresolved inflammatory response 15-17. 
Moreover, in two patients, diffuse lung disease have also been associated with SP-C deficiency 
without any detectable SFTPC mutation9. Thus, Alteration of SP-C metabolism or complete SP-
C deficiency is critical in diffuse lung disease pathophysiology. 
Interestingly, we found three novel variants, L188P, C189Y and L194P, located in the 
C-terminus of proSP-C BRICHOS domain (F94-I197)—a highly conserved domain. The 
BRICHOS domain is composed of about 100 amino acids in the proprotein. It is found in 
several proteins associated with degenerative and proliferative diseases 18. The BRICHOS 
domain is thought to be involved in protein processing and is assumed to have a chaperone-like 
function. It plays a critical role in proSP-C targeting and processing 16, 19, 20. Indeed, in previous 
studies, two patients have been found to carry a mutation encoding substitution (L188R and 
L188Q) of the same conserved leucine residue altered in our cohort (L188P). The L188R 
mutation has been detected in one infant with ILD 5. On the other hand, the L188Q mutation is 
detected in large familial pulmonary fibrosis kindred, either in children or adults with cellular 
interstitial pneumonitis or usual interstitial pneumonitis 6. We have observed L188P in an 18-
year-old patient who had diffuse lung disease during the first year of life. Unfortunately, 
familial samples were not available.  
Descriptions of the reported new mutations will be the subject of further functional 
studies, which will improve knowledge on the pathogenesis of associated surfactant diffuse 
lung disease in children.  
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TABLE AND FIGURES LEGENDS 
 
Table 1: Newly discovered SFPTC mutations. 
Table 2: Characteristics of patients with I73T and new SFTPC mutations. 
 
Figure 1: Pedigree of families with the new SFTPC mutations C189Y and L194P. 
Figure 2: Localization of new SFTPC Mutations. Schematic representation of SFTPC gene. 
(a) (exon I to VI), corresponding mRNA (b), pro-SP-C (c) and SP-C (d) protein sequence with 
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